EFFICIENCY AND SAFETY OF CHEMOTHERAPY REGIMEN WITH SQ109 IN THOSE SUFFERING FROM MULTIPLE DRUG RESISTANT TUBERCULOSIS

The objective of the study: to assess efficiency and safety of SQ109 used within standard treatment regimens for multiple drug resistant tuberculosis (MDR TB)Subjects and Methods A multi-center, double, blind, randomized, placebo-controlled study was conducted in two parallel groups from September 2...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Tuberkulëz i bolezni lëgkikh Ročník 96; číslo 3; s. 6 - 18
Hlavní autori: Borisov, S. E., Bogorodskaya, E. M., Volchenkov, G. V., Kulchavenya, E. V., Maryandyshev, A. O., Skornyakov, S. N., Talibov, O. B., Tikhonov, A. M., Vasilyeva, I. A.
Médium: Journal Article
Jazyk:Russian
Vydavateľské údaje: New Terra Publishing House 01.04.2018
Predmet:
multiple drug resistance of m. tuberculosis
pulmonary tuberculosis
sq109
ISSN:2075-1230, 2542-1506
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Abstract The objective of the study: to assess efficiency and safety of SQ109 used within standard treatment regimens for multiple drug resistant tuberculosis (MDR TB)Subjects and Methods A multi-center, double, blind, randomized, placebo-controlled study was conducted in two parallel groups from September 21, 2012 to September 30, 2016, in 6 research centers located in 5 cities of the Russian FederationMain results 1 Cessation of bacillary excretion confirmed by cultures on liquid media by the end of the 6th month of the intensive phase of chemotherapy in pulmonary MDR TB patients receiving SQ109 was observed confidently more often versus treatment regimens containing only existing anti-tuberculosis drugs: both for ITT population (610% versus 429%, p = 00412), and PP population (797% versus 614%, p = 00486) 2 There were no statistically significant differences in the achievement of sputum conversion between the groups, but by the end of the 8th week, the sputum converted in 52% of patients in the group treated with SQ109 versus 38% in the group taking a placebo The median time of bacillary excretion cessation confirmed by culture on liquid media in SQ109 group made 56 days, while in the placebo group it was 84 days 3 Use of SQ109 along with basic chemotherapy for pulmonary MDR TB did not result in the higher frequency of adverse events, worsening of their severity, development of new variants of adverse events compared to the basic anti-tuberculosis treatment of this group of patients in combination with placebo 4 Results of the study allow concluding that SQ109 is an effective drug, satisfactory tolerated (compatible with tolerability of placebo) being a part of integral etiotropic chemotherapy of pulmonary MDR TB patients
AbstractList The objective of the study: to assess efficiency and safety of SQ109 used within standard treatment regimens for multiple drug resistant tuberculosis (MDR TB)Subjects and Methods A multi-center, double, blind, randomized, placebo-controlled study was conducted in two parallel groups from September 21, 2012 to September 30, 2016, in 6 research centers located in 5 cities of the Russian FederationMain results 1 Cessation of bacillary excretion confirmed by cultures on liquid media by the end of the 6th month of the intensive phase of chemotherapy in pulmonary MDR TB patients receiving SQ109 was observed confidently more often versus treatment regimens containing only existing anti-tuberculosis drugs: both for ITT population (610% versus 429%, p = 00412), and PP population (797% versus 614%, p = 00486) 2 There were no statistically significant differences in the achievement of sputum conversion between the groups, but by the end of the 8th week, the sputum converted in 52% of patients in the group treated with SQ109 versus 38% in the group taking a placebo The median time of bacillary excretion cessation confirmed by culture on liquid media in SQ109 group made 56 days, while in the placebo group it was 84 days 3 Use of SQ109 along with basic chemotherapy for pulmonary MDR TB did not result in the higher frequency of adverse events, worsening of their severity, development of new variants of adverse events compared to the basic anti-tuberculosis treatment of this group of patients in combination with placebo 4 Results of the study allow concluding that SQ109 is an effective drug, satisfactory tolerated (compatible with tolerability of placebo) being a part of integral etiotropic chemotherapy of pulmonary MDR TB patients
Author Bogorodskaya, E. M.
Skornyakov, S. N.
Talibov, O. B.
Volchenkov, G. V.
Tikhonov, A. M.
Kulchavenya, E. V.
Vasilyeva, I. A.
Borisov, S. E.
Maryandyshev, A. O.
Author_xml – sequence: 1
  givenname: S. E.
  surname: Borisov
  fullname: Borisov, S. E.
– sequence: 2
  givenname: E. M.
  surname: Bogorodskaya
  fullname: Bogorodskaya, E. M.
– sequence: 3
  givenname: G. V.
  surname: Volchenkov
  fullname: Volchenkov, G. V.
– sequence: 4
  givenname: E. V.
  surname: Kulchavenya
  fullname: Kulchavenya, E. V.
– sequence: 5
  givenname: A. O.
  surname: Maryandyshev
  fullname: Maryandyshev, A. O.
– sequence: 6
  givenname: S. N.
  surname: Skornyakov
  fullname: Skornyakov, S. N.
– sequence: 7
  givenname: O. B.
  surname: Talibov
  fullname: Talibov, O. B.
– sequence: 8
  givenname: A. M.
  surname: Tikhonov
  fullname: Tikhonov, A. M.
– sequence: 9
  givenname: I. A.
  surname: Vasilyeva
  fullname: Vasilyeva, I. A.
BookMark eNqNkU1vnDAQhlGVSkmT_Af3B9D6Axv7VFFiFksspHwo2pNlvHZFtF0q2Bz67-tN2hxyymlGM-_7jGbmU3RxnI8uij4j-AUjLPBXDFMaI0xgjCHisWAxiVmM-IfoCtMEx4hCdhHy_7LL6HZdHyEM4tBJ0FX0JItC5UrW-Q5k9R3oskL2O9AUIC_ltulL2Wb3O9DKjdrKGjyovgTdDwQFUDXoy6aToBuKQraq3oCibbZgO1S9uq8kuGuHTTB2quuzugf98F22-VA1oXATffTmsLrbf_E6GsLYvIyrZqPyrIotFoSHRSB3LrHUjnuRGku8F5454kXKeIpg4mE6OsLsKCg23nvH00SMxkJhgoSS60i9cPezedS_l-mXWf7o2Uz6uTAvP7VZTpM9OC2oJ9YglLi9SJJ9yjEzKIWU85R4OsLAEi8su8zrujj_ykNQP79Dn--sz3fW53dowTTRTCMevN_eeO10MqdpPp4WMx3eQfgLG6iI8w
CitedBy_id crossref_primary_10_1002_slct_201901303
crossref_primary_10_1089_mdr_2021_0424
crossref_primary_10_1042_BST20190950
crossref_primary_10_1016_j_tube_2020_101989
crossref_primary_10_1038_s41429_023_00629_8
crossref_primary_10_1128_AAC_00024_21
crossref_primary_10_1007_s00706_025_03341_5
crossref_primary_10_1038_s42003_022_03693_2
crossref_primary_10_1128_spectrum_03677_23
crossref_primary_10_3390_app10020623
crossref_primary_10_1016_j_cclet_2023_108464
crossref_primary_10_1007_s00436_019_06560_y
crossref_primary_10_1016_j_lanmic_2024_100992
crossref_primary_10_4155_fmc_2019_0038
crossref_primary_10_1016_j_tube_2022_102288
crossref_primary_10_3390_jpm12040569
crossref_primary_10_3390_ph18010070
crossref_primary_10_1007_s11094_020_02239_2
crossref_primary_10_1038_s41429_020_0291_8
crossref_primary_10_1080_17460441_2023_2218082
crossref_primary_10_1186_s12910_021_00617_3
crossref_primary_10_1038_s41573_024_00897_5
crossref_primary_10_3390_metabo11020088
crossref_primary_10_1186_s12941_024_00746_8
ContentType Journal Article
CorporateAuthor National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Moscow, Russian Federation
A. I. Yevdokimov State Medical Stomatological University, Moscow Russian Federation
Moscow Municipal Scientific Practical Center of Tuberculosis Control, Health Department of Moscow Russian Federation
Vladimir Regional TB Dispensary
Arkhangelsk Regional Clinical TB Dispensary, Arkhangelsk Russian Federation
Central Tuberculosis Research Institute, Moscow, Russian Federation
Novosibirsk Tuberculosis Research Institute, Novosibirsk, Russia
CorporateAuthor_xml – name: Vladimir Regional TB Dispensary
– name: Novosibirsk Tuberculosis Research Institute, Novosibirsk, Russia
– name: Moscow Municipal Scientific Practical Center of Tuberculosis Control, Health Department of Moscow Russian Federation
– name: National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Moscow, Russian Federation
– name: A. I. Yevdokimov State Medical Stomatological University, Moscow Russian Federation
– name: Central Tuberculosis Research Institute, Moscow, Russian Federation
– name: Arkhangelsk Regional Clinical TB Dispensary, Arkhangelsk Russian Federation
DBID AAYXX
CITATION
DOA
DOI 10.21292/2075-1230-2018-96-3-6-18
DatabaseName CrossRef
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
DatabaseTitleList
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
DeliveryMethod fulltext_linktorsrc
EISSN 2542-1506
EndPage 18
ExternalDocumentID oai_doaj_org_article_95f3ca114ed944d7826a17058873f5b0
10_21292_2075_1230_2018_96_3_6_18
GroupedDBID AAYXX
ADBBV
AHDHK
ALMA_UNASSIGNED_HOLDINGS
BCNDV
CITATION
GROUPED_DOAJ
IPNFZ
RIG
VCL
VIT
ID FETCH-LOGICAL-c2938-1808ee4c5cbd97ac3ff9f6e3f97687104f07be36cb952afffe8749bac09a97653
IEDL.DBID DOA
ISSN 2075-1230
IngestDate Fri Oct 03 12:39:34 EDT 2025
Sat Nov 29 02:53:50 EST 2025
Tue Nov 18 21:36:28 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Language Russian
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c2938-1808ee4c5cbd97ac3ff9f6e3f97687104f07be36cb952afffe8749bac09a97653
OpenAccessLink https://doaj.org/article/95f3ca114ed944d7826a17058873f5b0
PageCount 13
ParticipantIDs doaj_primary_oai_doaj_org_article_95f3ca114ed944d7826a17058873f5b0
crossref_primary_10_21292_2075_1230_2018_96_3_6_18
crossref_citationtrail_10_21292_2075_1230_2018_96_3_6_18
PublicationCentury 2000
PublicationDate 2018-04-01
PublicationDateYYYYMMDD 2018-04-01
PublicationDate_xml – month: 04
  year: 2018
  text: 2018-04-01
  day: 01
PublicationDecade 2010
PublicationTitle Tuberkulëz i bolezni lëgkikh
PublicationYear 2018
Publisher New Terra Publishing House
Publisher_xml – name: New Terra Publishing House
SSID ssj0001850641
Score 2.2092502
Snippet The objective of the study: to assess efficiency and safety of SQ109 used within standard treatment regimens for multiple drug resistant tuberculosis (MDR...
SourceID doaj
crossref
SourceType Open Website
Enrichment Source
Index Database
StartPage 6
SubjectTerms multiple drug resistance of m. tuberculosis
pulmonary tuberculosis
sq109
Title EFFICIENCY AND SAFETY OF CHEMOTHERAPY REGIMEN WITH SQ109 IN THOSE SUFFERING FROM MULTIPLE DRUG RESISTANT TUBERCULOSIS
URI https://doaj.org/article/95f3ca114ed944d7826a17058873f5b0
Volume 96
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 2542-1506
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0001850641
  issn: 2075-1230
  databaseCode: DOA
  dateStart: 20140101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Pa9swFBajjLHLWGlHu65FhV5F7ciWpaOb2I0hsTP_oM1JyLIEhZGVrNnf3yclC7l1hx4t-9ni6ZPf-8Tjewjd9K6yW_OBRJZx4gS5iBJwGQeRVVRFZhgNvtlEUpb88VEsDlp9uZqwrTzw1nG3IrZUK8jazSCiaICAxpSTgIHNQW3ce7YeJOKATPnTFS_E5tgW3IwJ_J6DT-ja1T1DfBvd7gcBJCFseEYoYcQ1_jgITgca_j7Y5F_Rl12WiNPt7I7Rh_XmBG0gpyz8mdASp-UEN2metUtc5djpGlTtNKvTxRLX2X0xz0r8ULRT3PwMA4GLErfTqslw0-W5F5HCeV3N8bybtcViluFJ3d2DYVM0bVq2uO3usnrczSoYOEUdfGY8JbuuCURD6AZKyANuTKRj3Q8iUZpaKywz1ELiAewI1iBIekOZ7kU8UtZaw5NI9EoHQsEjMf2Gjla_V-YMYW15qLi2MQ10xDgToUoSwXrWKyXEwM4R_-cuqXeS4q6zxS8J1MJ7WjpPS-dp6TwtBZNUMhnyczTamz5vdTX-x-jOrcnewElj-wEAjNwBRr4FmO_v8ZIL9Nkjx5fw_EBHL-uNuUQf9d-Xpz_rK4_FV1Dk0l8
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=EFFICIENCY+AND+SAFETY+OF+CHEMOTHERAPY+REGIMEN+WITH+SQ109+IN+THOSE+SUFFERING+FROM+MULTIPLE+DRUG+RESISTANT+TUBERCULOSIS&rft.jtitle=Tuberkul%C3%ABz+i+bolezni+l%C3%ABgkikh&rft.au=Borisov%2C+S.+E.&rft.au=Bogorodskaya%2C+E.+M.&rft.au=Volchenkov%2C+G.+V.&rft.au=Kulchavenya%2C+E.+V.&rft.date=2018-04-01&rft.issn=2075-1230&rft.eissn=2542-1506&rft.volume=96&rft.issue=3&rft.spage=6&rft.epage=18&rft_id=info:doi/10.21292%2F2075-1230-2018-96-3-6-18&rft.externalDBID=n%2Fa&rft.externalDocID=10_21292_2075_1230_2018_96_3_6_18
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2075-1230&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2075-1230&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2075-1230&client=summon